4-[(3-aminomethyl-6-trifluoromethyl-pyridin-2-ylamino)-methyl]-piperidine-1-carbonic acid tert-butyl ester | 935518-58-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[(3-aminomethyl-6-trifluoromethyl-pyridin-2-ylamino)-methyl]-piperidine-1-carbonic acid tert-butyl ester
• 英文别名: Tert-butyl 4-[[[3-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]amino]methyl]piperidine-1-carboxylate
• CAS: 935518-58-4
• 化学式: C₁₈H₂₇F₃N₄O₂
• 分子量: 388.433
• InChiKey: COHSKLJLHQCGGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  80.5
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-(3-fluoro-4-methylsulfonylaminophenyl)propionic acid 、 4-[(3-aminomethyl-6-trifluoromethyl-pyridin-2-ylamino)-methyl]-piperidine-1-carbonic acid tert-butyl ester 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以55%的产率得到tert-butyl 4-(((3-((2-(3-Fluoro-4-(methylsulfonamido)phenyl)propanamido)methyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as Potent Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists: Structure–Activity Relationships of 2-Amino Derivatives in the N-(6-Trifluoromethylpyridin-3-ylmethyl) C-Region

  摘要：

  A series of N-(2-amino-6-trifluoromethylpyridin-3-ylmethyl)-2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides were designed combining previously identified pharmacophoric elements and evaluated as hTRPV1 antagonists. The SAR analysis indicated that specific hydrophobic interactions of the 2-amino substituents in the C-region of the ligand were critical for high hTRPV1 binding potency. In particular, compound 49S was an excellent TRPV1 antagonist (K-i(CAP) = 0.2 nM; IC50(pH) = 6.3 nM) and was thus approximately 100- and 20-fold more potent, respectively, than the parent compounds 2 and 3 for capsaicin antagonism. Furthermore, it demonstrated strong analgesic activity in the rat neuropathic model superior to 2 with almost no side effects. Compound 49S antagonized capsaicin induced hypothermia in mice but showed TRPV1-related hyperthermia. The basis for the high potency of 49S compared to 2 is suggested by docking analysis with our hTRPV1 homology model in which the 4-methylpiperidinyl group in the C-region of 49S made additional hydrophobic interactions with the hydrophobic region.

  DOI：

  10.1021/jm300780p
• 作为产物：
  描述：

  2-氯-6-三氟甲基烟腈 在 sodium tetrahydroborate 、 nickel(II) chloride hexahydrate 作用下， 以 甲醇 为溶剂， 反应 28.0h， 生成 4-[(3-aminomethyl-6-trifluoromethyl-pyridin-2-ylamino)-methyl]-piperidine-1-carbonic acid tert-butyl ester
  参考文献：
  名称：

  2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as Potent Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists: Structure–Activity Relationships of 2-Amino Derivatives in the N-(6-Trifluoromethylpyridin-3-ylmethyl) C-Region

  摘要：

  A series of N-(2-amino-6-trifluoromethylpyridin-3-ylmethyl)-2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides were designed combining previously identified pharmacophoric elements and evaluated as hTRPV1 antagonists. The SAR analysis indicated that specific hydrophobic interactions of the 2-amino substituents in the C-region of the ligand were critical for high hTRPV1 binding potency. In particular, compound 49S was an excellent TRPV1 antagonist (K-i(CAP) = 0.2 nM; IC50(pH) = 6.3 nM) and was thus approximately 100- and 20-fold more potent, respectively, than the parent compounds 2 and 3 for capsaicin antagonism. Furthermore, it demonstrated strong analgesic activity in the rat neuropathic model superior to 2 with almost no side effects. Compound 49S antagonized capsaicin induced hypothermia in mice but showed TRPV1-related hyperthermia. The basis for the high potency of 49S compared to 2 is suggested by docking analysis with our hTRPV1 homology model in which the 4-methylpiperidinyl group in the C-region of 49S made additional hydrophobic interactions with the hydrophobic region.

  DOI：

  10.1021/jm300780p

文献信息

• NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS
  申请人：Lee Jeewoo

  公开号：US20070105861A1

  公开（公告）日：2007-05-10

  The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.

  本发明涉及新型辣椒素受体配体，以及用于其生产的方法，含有这些化合物的药物制剂以及利用这些化合物生产药物制剂的用途。
• Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
  申请人：Grünenthal GmbH

  公开号：EP2388258A1

  公开（公告）日：2011-11-23

  Die vorliegende Erfindung betrifft neue Vanilloid-Rezeptor-Liganden, Verfahren zu ihrer Herstellung, Arzneimittel enthaltend diese Verbindungen und die Verwendung dieser Verbindungen zur Herstellung von Arzneimitteln.

  本发明涉及新型类香草素受体配体、其制备工艺、含有这些化合物的药物以及使用这些化合物制备药物。
• NEUE VANILLOID-REZEPTOR LIGANDEN UND IHRE VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
  申请人：Grünenthal GmbH

  公开号：EP1940821A2

  公开（公告）日：2008-07-09
• Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations
  申请人：Gruenenthal GmbH

  公开号：US20140179686A1

  公开（公告）日：2014-06-26

  The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.
• US8710233B2
  申请人：——

  公开号：US8710233B2

  公开（公告）日：2014-04-29